白细胞介素-18 启动子多态性与血液透析患者乙型肝炎病毒表面抗原抗体的产生。

Interleukin-18 promoter polymorphism and development of antibodies to surface antigen of hepatitis B virus in hemodialysis patients.

机构信息

Department of Nephrology, Transplantology and Internal Diseases, Karol Marcinkowski University of Medical Sciences, Poznań, Poland.

出版信息

Kidney Blood Press Res. 2012;35(1):1-8. doi: 10.1159/000329932. Epub 2011 Aug 10.

DOI:10.1159/000329932

PMID:21832842

Abstract

BACKGROUND

Interleukin (IL)-18 is involved in hepatitis B virus (HBV) clearance and augments antibodies against surface antigen of HBV (anti-HBsAg) production during DNA vaccination. The IL-18 -1297C>T (rs360719) polymorphism may modulate the IL-18 expression.

AIM

To determine the potential association of IL-18 -1297C>T polymorphism with development of anti-HBsAg in hemodialysis (HD) patients.

METHODS

The frequency of IL-18 -1297C>T alleles and genotypes was identified by polymerase chain reaction restriction fragment length polymorphism in 435 HD patients. Group 1 (n = 219) developed an anti-HBsAg titer >10 IU/l as a result of vaccination or HBV transmission. Group 2 (n = 216) included patients who did not develop an anti-HBsAg titer >10 IU/l in response to at least one full series of vaccination or HBV transmission. The significance of genotype frequency was tested using the Fisher exact test.

RESULTS

In group 1, the frequencies of -1297CC, -1297CT and -1297TT genotypes were 7.3, 39.7 and 53.0%, respectively, and in group 2 they were 1.9, 42.1 and 56.0%, respectively. The odds ratio for CC versus CT + TT was 0.239 (95% CI 0.079-0.728, p = 0.010), and for CC versus TT it was 0.240 (95% CI 0.078-0.738, p = 0.009).

CONCLUSION

In HD patients, the IL-18 -1297CC genotype may play a role in anti-HBsAg development in response to HBV surface antigen.

摘要

背景

白细胞介素（IL）-18 参与乙型肝炎病毒（HBV）清除，并在 DNA 疫苗接种期间增强针对 HBV 表面抗原的抗体（抗-HBsAg）产生。IL-18-1297C>T（rs360719）多态性可能调节 IL-18 的表达。

目的

确定白细胞介素-18-1297C>T 多态性与血液透析（HD）患者抗-HBsAg 发展的潜在关联。

方法

通过聚合酶链反应限制片段长度多态性在 435 例 HD 患者中鉴定 IL-18-1297C>T 等位基因和基因型的频率。第 1 组（n=219）由于接种或 HBV 传播而产生抗-HBsAg 滴度>10IU/l。第 2 组（n=216）包括至少接受过一次完整系列接种或 HBV 传播但未产生抗-HBsAg 滴度>10IU/l 的患者。使用 Fisher 精确检验测试基因型频率的显著性。

结果

第 1 组中-1297CC、-1297CT 和-1297TT 基因型的频率分别为 7.3%、39.7%和 53.0%，第 2 组分别为 1.9%、42.1%和 56.0%。CC 与 CT+TT 的比值比为 0.239（95%CI 0.079-0.728，p=0.010），CC 与 TT 的比值比为 0.240（95%CI 0.078-0.738，p=0.009）。